Clinical-stage development risk
Product candidates may not demonstrate safety or efficacy in trials, which can halt development.
- Scope
- Lead programs in genetic and metabolic disease
- Materiality
- high
Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a Singapore-incorporated biotechnology company with operating subsidiaries in the United States, Japan, Ireland, and the United Kingdom. It develops oligonucleotide-based medicines designed to modulate RNA for genetic and other diseases, with programs spanning preclinical and clinical-stage therapeutic candidates.
317
6.47
6.35
| % | |
|---|---|
| Clinical-stage therapeutic programs | 0% Drug candidates in human testing, including programs for genetic and metabolic diseases. |
| Preclinical discovery programs | 0% Earlier-stage RNA medicines being designed and tested before clinical development. |
| Collaboration revenue | 100% Revenue recognized from partnered research and development agreements. |
Wave does not currently sell approved products; its economic counterparties are collaboration partners that fund or...
- Strategic collaboration partnersprimary
Pharma partners that pay for or co-fund discovery and development work under collaboration agreements.
- Future specialty prescriberssecondary
Physicians who would prescribe approved therapies in rare disease or metabolic settings.
- Future patientssecondary
Patients with genetic or metabolic diseases who would receive approved RNA medicines.
Wave is incorporated in Singapore but maintains principal operating presence in Cambridge, Massachusetts, with...
- •Singapore is the legal domicile and registered office location
- •Cambridge, Massachusetts is the principal U.S. operating base
- •Japan, Ireland, and the UK house wholly owned subsidiaries
- •Business is research-driven and not tied to product sales geography
Wave’s strategy centers on advancing RNA medicines through internal discovery and clinical development while using...
01
Advance lead therapeutic programsshort-term
Clinical progress is the main path to value creation in a pre-commercial biotech model.
02
Maintain and expand collaborationsmedium-term
Partnering helps fund development and can accelerate translation of programs.
03
Strengthen scientific and IP positionlong-term
Differentiated RNA chemistry and protected know-how are central to competition.
Wave is a clinical-stage biotechnology company with no approved product sales, so its business depends on successful...
Dependence on collaboration agreements
A meaningful portion of revenue comes from partner-funded work and can fluctuate with contract terms.
- Scope
- GSK and Takeda collaborations
- Materiality
- high
No commercial infrastructure
The company has no sales, marketing, or distribution capabilities for approved products.
- Scope
- Future commercialization
- Materiality
- high
Competition for talent and capital
Biotech development requires specialized scientists, trial sites, and funding in a crowded market.
- Scope
- R&D organization and pipeline execution
- Materiality
- medium
Third-party manufacturing and trial execution
CROs and CMOs are needed for preclinical and clinical work, creating operational dependency.
- Scope
- Drug substance and clinical supply chain
- Materiality
- medium
Collaboration revenue recognition
Affects reported collaboration revenue and quarterly comparability
CRO and CMO accrual estimates
Affects R&D expense and operating loss
Share-based compensation
Affects G&A and R&D expense levels
Lease accounting
Affects balance sheet liabilities and cash flow planning
Harmony Biosciences Holdings, Inc.
HRMY · Pharmaceutical Preparations
ENDRA Life Sciences Inc.
NDRA · Electromedical & Electrotherapeutic Apparatus
ProPhase Labs, Inc.
PRPH · Pharmaceutical Preparations
Cannabis Bioscience International Holdings, Inc.
CBIH · Services-Commercial Physical & Biological Research
CV Sciences, Inc.
CVSI · Pharmaceutical Preparations
Zivo Bioscience, Inc.
ZIVO · Biological Products, (No Diagnostic Substances)
: 29.4.2026